TY  - JOUR
AU  - Garassino, Marina Chiara
AU  - Cho, Byoung-Chul
AU  - Kim, Joo-Hang
AU  - Mazières, Julien
AU  - Vansteenkiste, Johan
AU  - Lena, Hervé
AU  - Jaime, Jesus Corral
AU  - Gray, Jhanelle E
AU  - Powderly, John
AU  - Chouaid, Christos
AU  - Bidoli, Paolo
AU  - Wheatley-Price, Paul
AU  - Park, Keunchil
AU  - Soo, Ross A
AU  - Poole, Lynne
AU  - Wadsworth, Catherine
AU  - Dennis, Phillip A
AU  - Rizvi, Naiyer A
PY  - 2020
DO  - 10.1016/j.lungcan.2020.06.032
UR  - http://hdl.handle.net/10668/15981
T2  - Lung cancer (Amsterdam, Netherlands)
AB  - In the phase II ATLANTIC study, durvalumab provided durable responses with acceptable tolerability in heavily pretreated patients with advanced NSCLC, across three independent patient cohorts defined by EGFR/ALK status and tumour PD-L1 expression....
LA  - en
KW  - ATLANTIC
KW  - Durvalumab
KW  - NSCLC
KW  - Overall survival
KW  - Safety
KW  - Antibodies, Monoclonal
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Cohort Studies
KW  - Humans
KW  - Lung Neoplasms
TI  - Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.
TY  - research article
VL  - 147
ER  -